In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $13.00. The company’s shares closed last Thursday at $8.50, close to its 52-week high of $9.06.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.7% and a 49.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Phasebio Pharmaceuticals, and Madrigal Pharmaceuticals.
CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.29, a 46.8% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $12.00 price target.
The company has a one-year high of $9.06 and a one-year low of $1.21. Currently, CymaBay Therapeutics has an average volume of 1.83M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.